Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech, Inc. (NASDAQ: SNES) generates news as a biotechnology company focused on fertility control for rodent management. Its announcements frequently highlight developments related to ContraPest®, Evolve Rat, and Evolve Mouse Birth Control, which are described as contraceptive products for rats and mice that fit into integrated pest management programs and reduce reliance on traditional rodenticides.
Investors and observers following SNES news will see regular updates on financial performance and growth in Evolve rodent birth control products. Quarterly press releases report record revenues, gross profit margins, and the share of revenue contributed by Evolve-branded products, as well as commentary on adjusted EBITDA and cash balances. These releases often discuss progress toward profitability and the impact of multi-channel distribution strategies.
Company news also covers operational and commercial milestones. Examples include the launch of Evolve Rat Birth Control on major e-commerce platforms and home improvement retailer websites, expanded retail coverage through partners and wholesalers, and municipal pilot deployments in U.S. cities. Additional updates describe international distribution relationships, such as the appointment of the Belize Raptor Center as an official distributor following regulatory approval in Belize.
Regulatory and capital markets activities appear in SenesTech’s news flow as well. The company issues press releases on warrant exercises, gross proceeds from financings, and participation in investor conferences. For readers tracking SNES, this news page offers a way to monitor how SenesTech reports on product adoption, distribution channels, municipal and community programs, and financing events over time.
SenesTech (NASDAQ: SNES) announced the expansion of its Evolve™ Rat Birth Control solution to Chicago's Old Town Special Service Area #48. The deployment will cover strategic alleyways throughout the SSA, which spans approximately 0.6 square miles and supports over 200 businesses.
The initiative, led by the Old Town Merchants and Residents Association (OTMRA), aims to address rodent control in a sustainable way. Evolve™, classified as a minimum-risk pesticide by the EPA, is designed to reduce fertility in both male and female rats without harming non-target animals, making it ideal for urban environments.
SenesTech (NASDAQ: SNES), a company specializing in fertility control solutions for animal pest populations, has announced its participation in the upcoming Lytham Partners 2025 Consumer & Technology Investor Summit. The virtual presentation is scheduled for Tuesday, August 19, 2025, at 3:30 p.m. ET.
Investors can access the webcast through the conference homepage or directly via the company-specific link, with replay options available afterward.
SenesTech (NASDAQ: SNES), the manufacturer of EPA-registered rodent birth control products, reported strong Q2 2025 financial results. The company achieved record revenue of $625,000, up 36% year-over-year, with Evolve™ Rodent Birth Control products growing 94% and representing 83% of total revenue.
Key highlights include record gross profit margin of 65.4%, improved from 54.2% in Q2 2024, and a net loss of $1.6 million. The company maintains a strong cash position of $11.2 million as of August 5, 2025, providing runway through 2027. SenesTech expanded its municipal pilot deployments across major U.S. cities and completed a move to a new automated manufacturing facility in July 2025.
SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has closed a warrant exercise transaction generating $6.3 million in gross proceeds. The transaction involved the exercise of existing warrants for 1,458,872 shares at $4.15 per share, with H.C. Wainwright acting as exclusive placement agent.
As part of the deal, SenesTech issued new unregistered short-term warrants to purchase 2,188,308 shares at $5.25 per share, with a purchase price of $0.125 per warrant. These new warrants, if fully exercised, could generate additional proceeds of $11.5 million. The company plans to use the net proceeds for working capital and general corporate purposes.
[ "Secured $6.3 million in immediate gross proceeds from warrant exercise", "Potential additional proceeds of $11.5 million if new warrants are fully exercised", "New warrants priced at $5.25, representing a 26.5% premium to previous warrant exercise price" ]SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced warrant exercise agreements that will generate $6.3 million in gross proceeds. The transaction involves the immediate exercise of existing warrants to purchase 1,458,872 shares at $4.15 per share.
As part of the deal, the company will issue new unregistered short-term warrants for 2,188,308 shares at an exercise price of $5.25 per share, with a purchase price of $0.125 per warrant. These new warrants will expire 15 months after the effective date of the resale registration statement. If fully exercised, the new warrants could generate additional proceeds of $11.5 million.
SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has scheduled its Second Quarter 2025 financial results announcement for Thursday, August 7, 2025, after market close.
The company will host a conference call at 5:00 p.m. Eastern time on the same day to discuss the results. Investors can access the live webcast through the company's Investor Relations website, with a replay available for 90 days following the presentation.
SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced the closing of a warrant exercise transaction that generated $4.4 million in gross proceeds. The transaction involved the exercise of existing warrants to purchase 1,458,872 shares of common stock at $2.90 per share.
As part of the transaction, the company issued new unregistered short-term warrants to purchase an additional 1,458,872 shares at $4.15 per share, with a purchase price of $0.125 per warrant. These new warrants expire 15 months after the effective date of the resale registration statement. If fully exercised, the new warrants could generate approximately $6.0 million in additional gross proceeds. H.C. Wainwright served as the exclusive placement agent for the transaction.
The company plans to use the net proceeds for working capital and general corporate purposes.
SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced warrant exercise agreements that will generate $4.4 million in gross proceeds. The transaction involves the immediate exercise of existing warrants to purchase 1,458,872 shares of common stock at $2.90 per share, with an expected closing date of July 1, 2025.
As part of the transaction, SenesTech will issue new unregistered short-term warrants to purchase an additional 1,458,872 shares at $4.15 per share, with a purchase price of $0.125 per warrant. These new warrants will be exercisable immediately and expire fifteen months after the effective date of the resale registration statement. If fully exercised, these new warrants could generate additional gross proceeds of approximately $6.0 million.
The company plans to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright is serving as the exclusive placement agent for the transaction.
SenesTech (NASDAQ: SNES) has reported successful results from major urban deployments of its Evolve™ Rat Birth Control solution in Hong Kong and San Francisco. The company's innovative approach combines fertility control with traditional rodenticide methods, demonstrating significant effectiveness in urban pest control.
In Hong Kong's high-density mixed-use building deployment, the company achieved dramatic reduction in rodent sightings and bait consumption within three months. Similar success was recorded in San Francisco, with notable decreases in rodent activity and new births. SenesTech is now preparing for a container-sized order from Hong Kong following these positive results.
SenesTech (NASDAQ: SNES) has successfully completed a nine-month field trial of Evolve™ Rat Birth Control at UC Irvine's University Hills residential community. The trial, conducted with Irvine Campus Housing Authority (ICHA), demonstrated 98% bait consumption across 267 stations, replacing traditional rodenticides with an eco-friendly solution.
The initiative, which began in September 2024, was driven by resident pressure to adopt safer pest management practices. The project supported the HOOT Group's efforts to promote owl nesting and reduce rodenticide use. Following the successful trial, ICHA is placing a multi-pallet restocking order for continued deployment and expansion.
FAQ
What is the current stock price of Senestech (SNES)?
What is the market cap of Senestech (SNES)?
